139 related articles for article (PubMed ID: 28793134)
1. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Katz MHG; Wang H; Cuddy A; You YN
JAMA Surg; 2017 Nov; 152(11):1086-1088. PubMed ID: 28793134
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
Tachon G; Frouin E; Karayan-Tapon L; Auriault ML; Godet J; Moulin V; Wang Q; Tougeron D
Eur J Cancer; 2018 May; 95():112-116. PubMed ID: 29519639
[No Abstract] [Full Text] [Related]
3. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome.
Kratz CP; Holter S; Etzler J; Lauten M; Pollett A; Niemeyer CM; Gallinger S; Wimmer K
J Med Genet; 2009 Jun; 46(6):418-20. PubMed ID: 19293170
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical double staining of CK8/18 and MLH1 or PMS2 in detecting the expression of mismatch repair protein in solid tumors].
Liu Y; Guo YH; Wu SL; Yue YW; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):520-523. PubMed ID: 33915664
[TBL] [Abstract][Full Text] [Related]
6. Pediatric duodenal cancer and biallelic mismatch repair gene mutations.
Roy S; Raskin L; Raymond VM; Thibodeau SN; Mody RJ; Gruber SB
Pediatr Blood Cancer; 2009 Jul; 53(1):116-20. PubMed ID: 19283792
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
8. Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy.
Warrier SK; Trainer AH; Lynch AC; Mitchell C; Hiscock R; Sawyer S; Boussioutas A; Heriot AG
Dis Colon Rectum; 2011 Dec; 54(12):1480-7. PubMed ID: 22067175
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
10. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair gene deficiency and genetic anticipation in Lynch syndrome: myth or reality?
Ponti G; Ruini C; Tomasi A
Dis Colon Rectum; 2015 Jan; 58(1):141-2. PubMed ID: 25489705
[No Abstract] [Full Text] [Related]
12. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
[TBL] [Abstract][Full Text] [Related]
13. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
14. Update on Lynch syndrome genomics.
Peltomäki P
Fam Cancer; 2016 Jul; 15(3):385-93. PubMed ID: 26873718
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
16. [Should we systematically screen for Lynch syndrome in patients with upper urinary tract carcinoma?].
Olagui GS; Pignot G; Rouquette A; Vieillefond A; Amsellem-Ouazana D; de Longchamps NB; Radenen B; Zerbib M; Terris B
Bull Cancer; 2014 Feb; 101(2):144-50. PubMed ID: 24556207
[TBL] [Abstract][Full Text] [Related]
17. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Chapel DB; Yamada SD; Cowan M; Lastra RR
Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
20. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
